Exelixis | Sponsor of KCRS20
Exelixis is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new products for difficult-to-treat cancers. Discovery efforts have resulted in 4 approved products available worldwide. The cabozantinib clinical development program focuses on evaluation of potential activity in new tumor types as well as combinations with other agents through ISTs, CTEP collaboration, and pivotal studies, including the COSMIC and CONTACT clinical trial programs. Exelixis continues to invest in expansion of our product pipeline through internal drug discovery and strategic business development opportunities. The educational resources provided on this site may include information about a product or use that is not approved by the FDA.
Exelixis is on a Mission to Help Cancer Patients Recover Stronger and Live Longer

Click each of the following images to access a downloadable PDF and/or brochures.

KidneyCAN thanks Exelixis for their generous support for KCRS21 as a Founding Partner.

KidneyCAN Platinum Guidestar Seal

KidneyCAN is a registered 501(c)(3) nonprofit grassroots organization dedicated to funding and finding a cure for kidney cancer.

Contact KidneyCAN

KidneyCAN, 8327 Germantown Avenue, Philadelphia, PA 19118